Please login to the form below

Not currently logged in


This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

Biologics set to revolutionise the gastrointestinal market

Biologics set to revolutionise the gastrointestinal market

Also contributing to the predicted market growth are recent product approvals such as Takeda's Takecab (vonoprazan) for gastroesophageal reflux disease, and Entvio (vedolizumab) for IBD.

Latest news

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Access to orphan drugs for rare cancers in EU28
Revisiting Instagram for pharma
In pharma, Instagram usage is increasing because it offers so many benefits to engage with patients and HCPs...
The one multichannel question you must ask
There is a question every marketer should ask when designing a multichannel communications strategy...